Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax presented 12 abstracts on its FDA-approved menin inhibitor Revuforj at the EHA 2026 Congress, highlighting robust activity across multiple acute leukemia subtypes. Real-world data from the ROAR study showed an 82% overall response rate and 64% complete remission rate in heavily pretreated relapsed/refractory patients with NPM1 mutated or KMT2A-rearranged AML.
Key figures
- Drug Name
- Revuforj (revumenib)
- Nup98r orr
- 28%
- Roar study orr
- 82%
- Save trial orr
- 88%
- Total abstracts
- 12
- Post hsct 1yr os
- 95%
- Roar study cr crh
- 64%
- Frontline combo crc
- 97%
- Roar study patients
- 11
- Save trial mrd negativity
- 68%
- Save trial transplant rate
- 45%
- Frontline combo mrd negativity
- 86%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.